Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Fortress Biotech Inc. | MB-207 | X-linked severe combined immunodeficiency (XSCID) - previously transplanted | Phase 2 | Ongoing | Intravenous | Genetic Disorder |
| Fortress Biotech Inc. | Dotinurad - (TOPAZ) | Tophaceous gout | Phase 3 | Ongoing | Oral | N/A |
| Fractyl Health, Inc. | Revita - (REMAIN-1) | Obesity | Phase 3 | Ongoing | Topical | Endocrinology |
| Fresh Tracks Therapeutics Inc. | Sofpironium bromide gel - (ARGYLE) | Primary Axillary Hyperhidrosis | PDUFA | Topical | N/A | |
| Fresh Tracks Therapeutics Inc. | Sofpironium Bromide - (Cardigan II) | Axillary Hyperhidrosis | Phase 3 | Topical | N/A | |
| Fresh Tracks Therapeutics Inc. | Sofpironium Bromide - (Cardigan) | Axillary hyperhidrosis | NDA Filing | Topical | N/A | |
| FTSE EPRA Europe Ex UK Dividend + | Qwo (collagenase clostridium histolyticum-aaes) - (APHRODITE-1) | Reduce Bruising following treatment of cellulite of the buttocks | Phase 2 | Subcutaneous | Wound Care | |
| FTSE EPRA Europe Ex UK Dividend + | XIAFLEX | Plantar Fibromatosis | Phase 2 | Intralesional injection | Orthopedic |
